SI3793995T1 - Zaviralci matrične metaloproteinaze (mmp)in načini njihove uporabe - Google Patents
Zaviralci matrične metaloproteinaze (mmp)in načini njihove uporabeInfo
- Publication number
- SI3793995T1 SI3793995T1 SI201930733T SI201930733T SI3793995T1 SI 3793995 T1 SI3793995 T1 SI 3793995T1 SI 201930733 T SI201930733 T SI 201930733T SI 201930733 T SI201930733 T SI 201930733T SI 3793995 T1 SI3793995 T1 SI 3793995T1
- Authority
- SI
- Slovenia
- Prior art keywords
- mmp
- inhibitors
- methods
- matrix metalloproteinase
- metalloproteinase
- Prior art date
Links
- 102000002274 Matrix Metalloproteinases Human genes 0.000 title 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671753P | 2018-05-15 | 2018-05-15 | |
| EP19728197.5A EP3793995B1 (en) | 2018-05-15 | 2019-05-14 | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
| PCT/US2019/032131 WO2019222157A1 (en) | 2018-05-15 | 2019-05-14 | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3793995T1 true SI3793995T1 (sl) | 2024-05-31 |
Family
ID=66690981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201930733T SI3793995T1 (sl) | 2018-05-15 | 2019-05-14 | Zaviralci matrične metaloproteinaze (mmp)in načini njihove uporabe |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US20190352288A1 (https=) |
| EP (4) | EP4335499A3 (https=) |
| JP (4) | JP7343571B2 (https=) |
| KR (3) | KR102861502B1 (https=) |
| CN (3) | CN112424186A (https=) |
| AU (3) | AU2019269409B2 (https=) |
| BR (1) | BR112020023269A2 (https=) |
| CA (2) | CA3100320A1 (https=) |
| DK (2) | DK3793995T3 (https=) |
| ES (2) | ES2978192T3 (https=) |
| FI (2) | FI3793992T3 (https=) |
| HU (2) | HUE066619T2 (https=) |
| LT (1) | LT3793995T (https=) |
| MY (1) | MY199200A (https=) |
| PL (1) | PL3793995T3 (https=) |
| PT (2) | PT3793992T (https=) |
| SG (2) | SG11202011316RA (https=) |
| SI (1) | SI3793995T1 (https=) |
| TW (3) | TWI827601B (https=) |
| WO (2) | WO2019222157A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10532102B2 (en) * | 2016-08-19 | 2020-01-14 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical composition and methods of uses |
| SI3793995T1 (sl) | 2018-05-15 | 2024-05-31 | Foresee Pharmaceuticals Usa, Inc. | Zaviralci matrične metaloproteinaze (mmp)in načini njihove uporabe |
| CA3158234A1 (en) * | 2019-11-14 | 2021-05-20 | Foresee Pharmaceuticals Co., Ltd. | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
| EP4351566A4 (en) * | 2021-06-08 | 2025-04-23 | Foresee Pharmaceuticals USA, Inc. | SAFE ADMINISTRATION OF MMP-12 INHIBITOR |
| TW202313011A (zh) * | 2021-06-08 | 2023-04-01 | 逸達生物科技股份有限公司 | Mmp抑制劑於治療急性呼吸窘迫綜合症之用途 |
| EP4198033A1 (en) | 2021-12-14 | 2023-06-21 | Basf Se | Heterocyclic compounds for the control of invertebrate pests |
| WO2023110473A1 (en) | 2021-12-14 | 2023-06-22 | Basf Se | Heterocyclic compounds for the control of invertebrate pests |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2482618A1 (fr) | 1980-05-16 | 1981-11-20 | Inst Corps Gras Iterg | Procede de conjugaison catalytique de corps gras polyinsatures, produits obtenus et application |
| US6352976B1 (en) | 1998-12-31 | 2002-03-05 | Aventis Pharmaceuticals Inc. | Selective inhibitors of MMP-12 |
| EP1150975A1 (en) | 1998-12-31 | 2001-11-07 | Aventis Pharmaceuticals Inc. | 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12 |
| EP1288199A4 (en) | 2000-04-28 | 2005-10-12 | Shionogi & Co | INHIBITORS OF MMP-12 |
| JP2004527511A (ja) | 2001-03-15 | 2004-09-09 | アストラゼネカ・アクチエボラーグ | メタロプロテイナーゼ阻害剤 |
| SE0100903D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| US6890915B2 (en) | 2001-05-25 | 2005-05-10 | Bristol-Myers Squibb Pharma Company | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| EP1394159A1 (fr) | 2002-08-13 | 2004-03-03 | Warner-Lambert Company LLC | Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
| SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| AU2003282920A1 (en) | 2002-10-04 | 2004-05-04 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) |
| US7132432B2 (en) * | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
| JP5042833B2 (ja) | 2004-08-19 | 2012-10-03 | クエスト ファーマシューティカル サーヴィシーズ | マクロファージエラスターゼの阻害剤としての５−［３−（４−ベンジルオキシフェニルチオ）−フラ−２−イル］−イミダゾリジン−２，４−ジオン及び類似体 |
| EP2797002A4 (en) | 2011-12-21 | 2015-05-20 | Panasonic Corp | DATA PROCESSING DEVICE, DATA TRANSMISSION DEVICE, DATA PROCESSING SYSTEM, DATA PROCESSING METHOD AND DATA TRANSMISSION METHOD |
| SI3793995T1 (sl) * | 2018-05-15 | 2024-05-31 | Foresee Pharmaceuticals Usa, Inc. | Zaviralci matrične metaloproteinaze (mmp)in načini njihove uporabe |
-
2019
- 2019-05-14 SI SI201930733T patent/SI3793995T1/sl unknown
- 2019-05-14 EP EP24150915.7A patent/EP4335499A3/en active Pending
- 2019-05-14 WO PCT/US2019/032131 patent/WO2019222157A1/en not_active Ceased
- 2019-05-14 EP EP24150920.7A patent/EP4349332A3/en active Pending
- 2019-05-14 US US16/411,336 patent/US20190352288A1/en not_active Abandoned
- 2019-05-14 US US17/055,483 patent/US12258335B1/en active Active
- 2019-05-14 HU HUE19728197A patent/HUE066619T2/hu unknown
- 2019-05-14 EP EP19731374.5A patent/EP3793992B1/en active Active
- 2019-05-14 LT LTEPPCT/US2019/032131T patent/LT3793995T/lt unknown
- 2019-05-14 CN CN201980047333.0A patent/CN112424186A/zh active Pending
- 2019-05-14 FI FIEP19731374.5T patent/FI3793992T3/fi active
- 2019-05-14 KR KR1020207035504A patent/KR102861502B1/ko active Active
- 2019-05-14 CA CA3100320A patent/CA3100320A1/en active Pending
- 2019-05-14 US US16/411,402 patent/US10851089B2/en active Active
- 2019-05-14 TW TW108116631A patent/TWI827601B/zh active
- 2019-05-14 JP JP2021514292A patent/JP7343571B2/ja active Active
- 2019-05-14 AU AU2019269409A patent/AU2019269409B2/en active Active
- 2019-05-14 PL PL19728197.5T patent/PL3793995T3/pl unknown
- 2019-05-14 DK DK19728197.5T patent/DK3793995T3/da active
- 2019-05-14 SG SG11202011316RA patent/SG11202011316RA/en unknown
- 2019-05-14 ES ES19728197T patent/ES2978192T3/es active Active
- 2019-05-14 AU AU2019270975A patent/AU2019270975B2/en active Active
- 2019-05-14 JP JP2021514291A patent/JP7344959B2/ja active Active
- 2019-05-14 DK DK19731374.5T patent/DK3793992T3/da active
- 2019-05-14 US US17/055,459 patent/US11739080B2/en active Active
- 2019-05-14 FI FIEP19728197.5T patent/FI3793995T3/fi active
- 2019-05-14 BR BR112020023269-6A patent/BR112020023269A2/pt unknown
- 2019-05-14 CN CN201980047375.4A patent/CN112424192B/zh active Active
- 2019-05-14 KR KR1020207035503A patent/KR102761591B1/ko active Active
- 2019-05-14 EP EP19728197.5A patent/EP3793995B1/en active Active
- 2019-05-14 ES ES19731374T patent/ES2984594T3/es active Active
- 2019-05-14 CN CN202411619226.XA patent/CN119462623A/zh active Pending
- 2019-05-14 PT PT197313745T patent/PT3793992T/pt unknown
- 2019-05-14 KR KR1020257002624A patent/KR20250021604A/ko active Pending
- 2019-05-14 PT PT197281975T patent/PT3793995T/pt unknown
- 2019-05-14 CA CA3100319A patent/CA3100319A1/en active Pending
- 2019-05-14 HU HUE19731374A patent/HUE066627T2/hu unknown
- 2019-05-14 TW TW108116632A patent/TWI798435B/zh active
- 2019-05-14 TW TW112115526A patent/TWI895726B/zh active
- 2019-05-14 WO PCT/US2019/032127 patent/WO2019222154A1/en not_active Ceased
- 2019-05-14 MY MYPI2020005983A patent/MY199200A/en unknown
- 2019-05-14 SG SG11202011318QA patent/SG11202011318QA/en unknown
-
2023
- 2023-07-06 US US18/347,674 patent/US12215096B2/en active Active
- 2023-08-31 JP JP2023140718A patent/JP2023164905A/ja active Pending
- 2023-09-04 JP JP2023142664A patent/JP7656669B2/ja active Active
-
2024
- 2024-01-18 AU AU2024200323A patent/AU2024200323B2/en active Active
- 2024-12-17 US US18/983,692 patent/US20250115590A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202011316RA (en) | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof | |
| IL287751A (en) | Kcnt1 inhibitors and methods of use | |
| DK3870579T3 (da) | Tyk2-inhibitorer og anvendelser deraf | |
| IL287768A (en) | Kcnt1 inhibitors and methods of use | |
| SG11202107614PA (en) | Pcsk9 inhibitors and methods of use thereof | |
| IL283592A (en) | Inhibitors of apol1 and methods of using same | |
| SG11202107615TA (en) | Pcsk9 inhibitors and methods of use thereof | |
| IL279475A (en) | Actonucleotidase inhibitors and methods of using them | |
| ZA202407941B (en) | Arginase inhibitors and methods of use thereof | |
| IL287973A (en) | acss2 inhibitors and methods of their use | |
| IL274504A (en) | 2ACSS inhibitors and methods of their use | |
| IL282350A (en) | Bernani-RGMC inhibitors and their use | |
| IL278989A (en) | MASP-2 suppressors and methods of using them | |
| IL280924A (en) | Arginase inhibitors and methods of using them | |
| IL286485A (en) | Pi4-kinase inhibitors and methods of using the same | |
| PT4058437T (pt) | Inibidores de metaloproteinases de matriz (mmp) e métodos de uso dos mesmos | |
| HK40049706A (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| HK40050318A (en) | Masp-2 inhibitors and methods of use |